Medicus Pharma received FDA clearance to start a Phase 2b clinical trial for SkinJect, a minimally invasive treatment targeting basal cell carcinoma in Gorlin syndrome patients. This rare genetic disorder causes multiple basal cell lesions, with no current FDA-approved noninvasive treatments available. The trial will enroll up to 50 patients, aiming to support a New Drug Application if successful. Patient recruitment is expected to begin by the end of the year, marking a key step toward commercializing SkinJect and addressing a significant unmet medical need.
Trust Carbon Infrastructure unveiled its HXS compute-efficiency layer, which reduces energy consumption by up to 50.5% and increases server throughput by 167% on NVIDIA H100 GPUs without changing AI model outputs. Tested on models from Alibaba, Meta,...
Bob Diamond, former Barclays CEO, predicts the CLARITY Act will pass by the end of 2026, benefiting Circle and Hyperliquid. The act sets clear rules for stablecoin yields, reducing legal uncertainty and enabling product expansion. Circle's USDC stabl...
Bitcoin wallets can be secured using randomness generated by rolling a six-sided die about 50 to 99 times, providing strong entropy without relying on electronic devices. This method gained attention after a Coldcard hardware wallet flaw exposed keys...
Applied Materials reported a record Q2 FY2026 revenue of $7.91 billion, an 11% increase year-over-year, and a non-GAAP EPS of $2.86, up 20%. The company raised its equipment growth guidance for calendar year 2026 to over 30%, driven by strong perform...
Collegium Pharmaceutical is transforming from a pain-management company to a central nervous system (CNS) platform by acquiring AZSTARYS, an ADHD drug franchise. The $650 million acquisition, funded by cash and debt, is projected to generate $60–70 m...
